Your example makes all of the sense in the world but the harsh reality is the system is set up where unfortunately that it does not matter. Manage Care Plans which are in my professional opinion are the thieves of our health care system it's not all about the Pharma Companies. They can say that the generic V is approved by the FDA as a bio-equivalent to the brand and is much cheaper for the patients and significantly less impact to our overall healthcare system. It's just the way our system is set up. Pharma companies will not Sue Manage Care Plans for infringement. Once again Pharma companies can sue each other for promoting a drug off able and then is taken up by the FDA as wel. I hope this helps. The bottom line is our Reduce IT Indication will take a major and I mean major hit if we loose the Appeals Case here in the US. Lets hope the CAFC Judges' decision is based on the law and precedent to this type of patent case. I for one am very confident Amarin will win this appeals case and and the decision will be overturned. I know everyone keeps saying it's a coin flip because that's just the way it's been over the past several years with appeal cases. Judge Shi-Head made way too many procedural and factual errors in this case that's not going to overlooked by the CAFC Judges. Take care.
News 
Market Data 
Discover 
AI
